文献速递心力衰竭与心肌病

TriageHF Plus 路径用于心衰器械远程监测的经济学评价

Economic evaluation of the TriageHF Plus clinical pathway for device-based remote monitoring in heart failure.
PubMed 文献 · Heart · 2026-08-25

基于 TriageHF Plus 多中心研究(758 例)构建经济学模型,评估该路径对比常规护理的终身成本与获益;在 300 例规模中心,5 年预计预防 384 次住院,人均终身节省 £3989 且更有效,99.4% 模拟中具成本节约优势。

要点

  • TriageHF Plus 路径在 99.4% 模拟中更有效且节省成本。
  • 300 例规模中心 5 年预计预防 384 次住院。
  • 人均终身节省 £3989,避免 1 次住院需 1.7 人终身使用。

核心结论

  • TriageHF Plus 路径对植入兼容 CIED 的心衰患者远程监测具有成本效益。

研究设计与样本

  • 基于 TriageHF Plus 多中心研究(758 例,NCT04177199)构建经济学模型,模拟 300 例合格患者规模的终身成本与获益。
  • 模型效能与资源使用参数来自个体患者水平数据分析,效用与单位成本取自已发表文献和国家数据库。
  • 成本与获益按每年 3.5% 贴现至现值。

主要发现

  • 300 例规模中心,TriageHF Plus 预计 5 年预防 384(363–405)次住院。
  • 对比常规护理,人均终身节省 £3989(£1812–£5563),且在 99.4% 模拟中更有效且节省成本。
  • 结果对关键输入参数变化稳健;避免 1 次住院需 1.7 人终身使用 TriageHF Plus。

临床怎么用

  • 对于植入兼容 CIED 的心衰患者,可考虑采用 TriageHF Plus 路径进行远程监测以降低住院并节省成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2024, the UK National Institute of Health and Care Excellence (NICE) recommended TriageHF alerts as an option for remote monitoring of patients with heart failure (HF) and a compatible cardiac implantable electronic device (CIED). Data on the cost-effectiveness of this approach has not been published. This research evaluates the cost-effectiveness of TriageHF Plus in public hospital settings, using data from the TriageHF Plus multicentre study (758 participants, NCT04177199). METHODS: An economic model was developed to capture the lifetime cost and benefits of TriageHF Plus versus usual care, based on a site of 300 eligible patients. Analysis on individual patient-level data informed model efficacy and resource use parameters. EuroQol five-dimensional questionnaire data and unit costs were obtained from published, peer-reviewed literature and national databases respectively. Costs and benefits were discounted at 3.5% per annum to adjust future costs and benefits to present value. RESULTS: In a site size of 300, TriageHF Plus was predicted to prevent 384 (363-405) hospitalisations over 5 years. In total, TriageHF Plus saved £3989 (£1812-£5563) per person-lifetime versus usual care and was more effective and cost-saving in 99.4% of simulations. Results were robust to changes in key input parameters. Modelling showed that to avoid one hospitalisation, 1.7 people would need lifetime access to TriageHF Plus. CONCLUSION: The TriageHF Plus pathway is cost-effective for the remote monitoring of HF in patients with CIEDs. TRIAL REGISTRATION NUMBER: NCT04177199.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Ahmed, Harwood, Lanctin, et al. Economic evaluation of the TriageHF Plus clinical pathway for device-based remote monitoring in heart failure. Heart. 2026. PMID: 41407535. doi:10.1136/heartjnl-2025-326702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。